Extracorporeal Cardiopulmonary Resuscitation (ECPR) Devices Market Size, Trends & Growth Opportunity By Product Type (ECPR Systems, Cannulation Kits, Perfusion Pumps, Oxygenators), By Technology Architecture, By Clinical Indication, By Regulatory Pathway, By Region and Forecast Till 2030

Report ID : AMR1006170 | Industries : Healthcare | Published On :September 2026 | Page Count : 274

Request Sample
Ask for Customization

ECPR Devices Market Overview and Definition

The global ECPR devices market covers the systems, disposable circuits and supporting equipment used to deliver extracorporeal cardiopulmonary resuscitation, a mechanical circulatory support technique that establishes emergency extracorporeal blood flow and oxygenation during cardiac arrest resuscitation efforts. This report describes the category strictly as a market segment: product types, technology architectures, clinical indications, care settings and regulatory pathways, never as a statement of clinical effectiveness, survival benefit or treatment outcome for any specific device, technique or company.

The market spans eleven product categories, from complete ECPR systems and ECMO-based ECPR platforms through to the cannulation kits, perfusion pumps, oxygenators, heat exchangers, monitoring systems and disposable circuits that make up a deployed circuit, alongside integrated emergency response solutions that bundle several of these components into a single deployable unit.

It makes no claim about survival rate, neurological outcome, or clinical effectiveness for any product, technique or company described on this page or across the linked pages that follow it. Four technology architectures, conventional ECMO-based, compact mobile, integrated automated and hybrid, structure how a system is engineered and deployed, and this dimension shapes which of four portability tiers, fixed hospital, mobile in-hospital, ambulance deployable and field deployable, a given system belongs to.

Nine clinical indications, from out-of-hospital and in-hospital cardiac arrest through cardiogenic shock, pulmonary embolism and post-cardiotomy support to bridge-to-recovery and bridge-to-transplant scenarios, define the settings this report tracks, alongside three patient populations, adult, pediatric and neonatal, and seven care setting categories spanning academic medical centres, university hospitals, cardiac specialty centres, trauma centres, emergency departments, intensive care units and military medical facilities.

Buyers in this market range from high-volume ECMO reference centres and specialised cardiac institutes to regional referral hospitals and community hospitals building initial ECPR capability, each approaching procurement through a different mix of direct tender, group purchasing organisation procurement, framework agreements and multi-year technology contracts, with contract values typically spanning below US$100,000 for individual disposable components to above US$500,000 for a complete integrated automated platform.

Five procurement models, direct capital purchase, leasing, managed equipment service, outcome-based procurement and consortium purchasing, and five regulatory pathways, FDA clearance, CE marking, PMDA approval, NMPA approval and country-specific approvals, together determine how quickly a given institution can move from budget approval to a deployed system.

Market Size and Growth Forecast (2026 to 2030)

The global ECPR devices market is estimated at approximately USD 420 Million in 2025 and is projected to reach approximately USD 680 Million by 2030, expanding at a compound annual growth rate of roughly 10.1 percent. This estimate is derived from independently published ECMO device market research narrowed to the ECPR-specific share of that broader category, documented in full in the Research Methodology section below.

Europe leads current demand, anchored by established ECMO reference centre networks across Germany, France, the United Kingdom, Italy, Spain, the Netherlands and Switzerland, while North America follows closely on the strength of high-volume academic ECMO programmes. Middle East and Africa is the fastest-growing region tracked in this report, reflecting expanding national resuscitation programme investment in GCC countries, with a full breakdown of regional demand appearing further down this page.

ECPR systems and ECMO-based ECPR platforms represent the largest product category by installed base, reflecting the concentration of current deployment within established, fixed hospital ECMO programmes, while portable and field deployable ECPR systems are the fastest-growing product category, tracking the broader shift toward extending ECPR-capable response beyond fixed hospital walls into ambulance and mobile response team settings.

Out-of-hospital cardiac arrest is the largest clinical indication by device deployment volume, and bridge-to-recovery indications are the fastest-growing, reflecting expanding use of ECPR as a stabilisation step ahead of definitive cardiac intervention rather than solely as a terminal rescue measure.

Academic medical centres and university hospitals account for the largest care setting category by installed base, while emergency departments and ambulance and EMS providers represent the fastest-growing care setting category as field deployable and ambulance deployable systems extend adoption beyond fixed hospital walls. Adult patients represent the largest patient population category, while pediatric ECPR programmes are growing at a faster pace off a smaller installed base as academic centres expand dedicated pediatric ECMO capacity.

MetricValue
Market Size (2025)Approximately USD 420 Million
Forecast Size (2030)Approximately USD 680 Million
CAGR (2025-2030)Approximately 10.1%
Base Year2025
Forecast Period2026-2030 (5-year)
Largest Product TypeECPR Systems and ECMO-Based ECPR Platforms
Fastest-Growing Product TypePortable and Field Deployable ECPR Systems
Largest RegionEurope
Fastest-Growing RegionMiddle East and Africa

Market Drivers

Expansion of hospital and regional ECMO programme capacity, increasing the installed base of centres equipped to deploy ECPR for both in-hospital and out-of-hospital cardiac arrest cases.

National resuscitation programme modernisation and emergency medicine investment across several covered countries, prioritising rapid mechanical circulatory support pathways as part of broader cardiac arrest response infrastructure.

Growing adoption of portable and field-deployable ECPR platforms, extending ECPR-capable response beyond fixed hospital systems into ambulance and mobile response team settings.

Rising institutional focus on simplifying deployment through automated and integrated ECPR platforms, aimed at broadening the pool of teams able to operate a system beyond specialist perfusion staff alone.

Increasing formation of shared regional ECPR networks and public-private emergency response programmes, broadening the addressable buyer base beyond high-volume academic ECMO centres to regional referral hospitals.

Growth in specialised cardiac institutes and dedicated ECMO centres of excellence, each representing a concentrated, repeat-purchase buyer segment for cannulation kits, oxygenators and disposable circuits.

Expanding pediatric and neonatal ECMO programme capacity at academic medical centres, a smaller but steadily growing patient population segment within the broader market.

MARKET SHIFT

Demand is steadily shifting from fixed hospital ECMO suites toward compact mobile and field deployable architectures, as regional networks and public-private emergency response programmes look to extend ECPR-capable response beyond the walls of high-volume academic centres.

 

Market Restraints

High capital cost of ECPR systems and associated disposable circuits, concentrating adoption among institutions with dedicated cardiac services or critical care capital budgets able to absorb a single purchase in the US$250,000 to above US$500,000 contract value band.

Reimbursement constraints across several covered countries, creating uncertainty around outcome-based and consortium procurement pathways that depend on multi-year budget commitments.

Significant training and service infrastructure requirements for ECMO-capable teams, slowing adoption at community and regional hospitals that lack existing perfusion expertise or a dedicated ECMO programme director.

Regulatory approval timelines spanning FDA clearance, CE marking, PMDA and NMPA approval pathways, which can delay newer automated and compact platform designs from reaching multiple regions simultaneously.

Long sales cycles, frequently extending from twelve to twenty-four months for capital equipment committee approval, particularly at public hospitals and government healthcare systems with formal tender processes.

PROCUREMENT INSIGHT

Managed equipment service and leasing structures are increasingly used to bridge the capital cost barrier at regional referral hospitals and community hospitals, converting a large upfront purchase into an operating expense a capital equipment committee can approve more quickly.

 

Market Opportunities

Technology opportunity areas in AI-assisted deployment and remote monitoring integration for ECPR platforms represent an emerging area of vendor differentiation, particularly for teams operating outside high-volume academic centres.

Clinical workflow gaps around cannulation speed and team coordination create room for platforms engineered around simplified, standardised deployment protocols suited to non-specialist emergency teams.

Portability gaps between fixed hospital systems and true field-deployable platforms remain an underserved segment as ambulance and mobile response team adoption grows across Western Europe and North America.

Cost optimisation opportunities through managed equipment service and consortium purchasing models are widening addressable demand among regional referral hospitals and community hospitals that could not previously justify a direct capital purchase.

Emerging market opportunities in GCC countries and East Asia, where national resuscitation programme investment is expanding ECMO reference centre capacity, position vendors with regulatory coverage across PMDA, NMPA and country-specific approval pathways to capture early adoption.

Product Types, Technology Architecture and Portability

Eleven product categories, from complete ECPR systems and ECMO-based platforms through cannulation kits, perfusion pumps and oxygenators, sit across four technology architectures and four portability tiers, and this spread of product types and technology architecture shapes which systems a fixed hospital programme, a mobile response team or an ambulance deployable service can realistically operate.

Clinical Indications, Patient Populations and Care Settings

Nine clinical indications spanning out-of-hospital cardiac arrest through bridge-to-transplant scenarios, three patient populations and seven care setting categories define where and for whom ECPR devices are deployed, and this clinical indication and care setting profile determines which population a given site is actually equipped to treat before any purchase decision is made.

Deployment Models, Procurement Models and End Users

Four deployment models, five procurement models and six end user categories connect how an ECPR system reaches a buyer to who ultimately operates it, and this deployment and procurement structure shapes contract value bands, sales cycle length and which end users pursue outcome-based versus consortium purchasing.

Regulatory Pathways and Compliance

FDA cleared, CE marked, PMDA and NMPA approved systems, alongside country-specific approval pathways, structure which ECPR devices a given market can access, and this regulatory pathway coverage determines how quickly a newer automated or compact platform design can reach multiple regions simultaneously.

Extracorporeal Cardiopulmonary Resuscitation (ECPR) Devices Market, By Region

Europe, North America, Asia-Pacific, Middle East and Africa, and Latin America each carry a distinct ECPR adoption profile, reflecting differences in ECMO programme maturity, national resuscitation programme investment and regulatory pathway coverage.

Europe leads current demand, anchored by established ECMO reference centre networks across Germany (Freiburg, Berlin, Munich, Hamburg, Cologne), France (Paris, Lyon, Marseille), the United Kingdom (London, Birmingham, Manchester), Italy (Milan, Rome), Spain (Madrid, Barcelona), the Netherlands (Amsterdam, Rotterdam) and Switzerland (Zurich, Basel), supported by the region's CE marking pathway and long-standing academic ECMO programme density.

North America follows closely, led by high-volume academic ECMO centres across the United States (Boston, Houston, Cleveland, Chicago, New York, Los Angeles) and Canada (Toronto, Montreal, Vancouver), with FDA clearance as the governing regulatory pathway and a growing base of shared regional ECPR networks.

Asia-Pacific spans established programmes in Japan (Tokyo, Osaka) and South Korea (Seoul, Busan) alongside expanding capacity in China (Beijing, Shanghai, Shenzhen), Australia (Sydney, Melbourne) and Singapore, with PMDA and NMPA approval pathways shaping which platforms reach each market first.

Middle East and Africa is the fastest-growing region tracked in this report, led by Saudi Arabia (Riyadh, Jeddah) and the United Arab Emirates (Dubai, Abu Dhabi) as GCC national resuscitation programme investment expands ECMO reference centre capacity, alongside emerging activity in South Africa (Johannesburg, Cape Town).

Latin America remains an earlier-stage but developing market, concentrated in Brazil (Sao Paulo, Rio de Janeiro) and Mexico (Mexico City, Monterrey), where academic medical centres are establishing initial ECMO reference centre capacity.

REGIONAL OPPORTUNITY

GCC countries are emerging as the fastest-growing regional segment as national resuscitation programme investment expands ECMO reference centre capacity ahead of broader regional adoption, positioning vendors with PMDA, NMPA and country-specific regulatory coverage to capture early demand.

 

Leading Companies

Twenty companies spanning global life-support manufacturers, specialist ECPR and ECMO platform companies, and emerging innovators and academic spin-off companies are profiled in our overview of leading ECPR device manufacturers.

Beyond This Page

This page provides the overall market size, growth trajectory and segmentation summary for the global ECPR devices market. The full report goes substantially further, with detailed pricing structures, contract value benchmarking, individual company revenue indicators and full regional and country-level sizing figures not published on this website.

The full report also includes detailed competitive benchmarking across product portfolio depth, installed base, distribution reach, service network and regulatory coverage, together with strategic recommendations on geographic expansion priorities, partnership priorities and product development priorities for vendors evaluating this market.

Buyers evaluating a first-time ECPR programme investment, and vendors assessing where to prioritise regulatory filings or channel investment, will find the full report's country-level sizing and competitive benchmarking sections particularly relevant to that decision.

Frequently Asked Questions

The market is estimated at approximately USD 420 Million in 2025 and is projected to reach approximately USD 680 Million by 2030, expanding at a compound annual growth rate of roughly 10.1 percent.

A category of systems and components, including complete ECPR systems, cannulation kits, perfusion pumps, oxygenators and monitoring equipment, used to establish emergency extracorporeal blood flow during cardiac arrest resuscitation efforts. This report describes the category strictly as a market segment, not as a statement of clinical effectiveness.

ECPR systems and ECMO-based ECPR platforms represent the largest product category by installed base, reflecting concentration within established, fixed hospital ECMO programmes.

Europe leads current demand, anchored by established ECMO reference centre networks across Germany, France, the United Kingdom, Italy, Spain, the Netherlands and Switzerland.

Middle East and Africa is the fastest-growing region tracked in this report, reflecting expanding national resuscitation programme investment in GCC countries.

Four architectures: conventional ECMO-based ECPR, compact mobile ECPR systems, integrated automated ECPR platforms and hybrid ECPR solutions, each shaping which portability tier a system belongs to.

Nine indications tracked in this report, including out-of-hospital and in-hospital cardiac arrest, cardiogenic shock, pulmonary embolism, post-cardiotomy support, and bridge-to-recovery and bridge-to-transplant scenarios.

FDA clearance, CE marking, PMDA and NMPA approval, and country-specific approval pathways, each shaping which markets a given ECPR system can access.

Twenty companies are profiled in this report, spanning global life-support manufacturers, specialist ECPR and ECMO platform companies, and emerging innovators and academic spin-off companies.

Inquire Before Buying Request Free Sample Ask For Discount

1. Introduction

1.1. Objective of the Study

1.2. Market Definition

1.3. Market Scope

2. Executive Summary

3. Extracorporeal Cardiopulmonary Resuscitation (ECPR) Devices Market Analysis and Forecast (2026–2030)

3.1. Overview

3.2. Market Dynamics

3.3. Drivers

3.3.1. Expansion of Hospital and Regional ECMO Programme Capacity, Increasing the Installed Base of Centres Equipped to Deploy ECPR for Both In-Hospital and Out-of-Hospital Cardiac Arrest Cases.

3.3.2. National Resuscitation Programme Modernisation and Emergency Medicine Investment in Several Covered Countries, Prioritising Rapid Mechanical Circulatory Support Pathways as Part of Broader Cardiac Arrest Response Infrastructure.

3.3.3. Growing Adoption of Portable and Field-Deployable ECPR Platforms, Extending ECPR-Capable Response Beyond Fixed Hospital Systems into Ambulance and Mobile Response Team Settings.

3.3.4. Rising Institutional Focus on Reducing Time-to-Cannulation Through Automated and Integrated ECPR Platforms That Simplify Deployment for Non-Specialist Emergency Teams.

3.3.5. Increasing Formation of Shared Regional ECPR Networks and Public-Private Emergency Response Programmes, Broadening the Addressable Buyer Base Beyond High-Volume Academic ECMO Centres.

3.4. Restraints

3.4.1. High Capital Cost of ECPR Systems and Associated Disposable Circuits, Concentrating Adoption Among Institutions with Dedicated Cardiac Services or Critical Care Capital Budgets.

3.4.2. Reimbursement Constraints Across Several Covered Countries, Creating Uncertainty Around Outcome-Based and Consortium Procurement Pathways.

3.4.3. Significant Training and Service Infrastructure Requirements for ECMO-Capable Teams, Slowing Adoption at Community and Regional Hospitals Without Existing Perfusion Expertise.

3.4.4. Regulatory Approval Timelines Across FDA, CE Marking, PMDA and NMPA Pathways That Can Delay Newer Automated and Compact Platform Designs from Reaching Multiple Regions Simultaneously.

3.5. Opportunities

3.5.1. Technology Opportunity Areas in AI-Assisted Deployment and Remote Monitoring Integration for ECPR Platforms, an Emerging Area of Vendor Differentiation.

3.5.2. Clinical Workflow Gaps Around Cannulation Speed and Team Coordination, Creating Room for Platforms Engineered Around Simplified, Standardised Deployment Protocols.

3.5.3. Portability Gaps Between Fixed Hospital Systems and True Field-Deployable Platforms, an Underserved Segment as Ambulance and Mobile Response Team Adoption Grows.

3.5.4. Cost Optimisation Opportunities Through Managed Equipment Service and Consortium Purchasing Models, Widening Addressable Demand Among Regional Referral Hospitals and Community Hospitals.

3.5.5. Emerging Market Opportunities in GCC Countries and East Asia, Where National Resuscitation Programme Investment Is Expanding ECMO Reference Centre Capacity.

3.6. Porter's Five Forces Model

3.7. Value Chain Analysis

4. By Product Type

4.1. ECPR Systems

4.2. Portable ECPR Systems

4.3. ECMO Based ECPR Platforms

4.4. Automated ECPR Platforms

4.5. Cannulation Kits

4.6. Perfusion Pumps

4.7. Oxygenators

4.8. Heat Exchangers

4.9. Monitoring Systems

4.10. Disposable Circuits

4.11. Integrated Emergency Response Solutions

5. By Technology Architecture

5.1. Conventional ECMO Based ECPR

5.2. Compact Mobile ECPR Systems

5.3. Integrated Automated ECPR Platforms

5.4. Hybrid ECPR Solutions

6. By Portability

6.1. Fixed Hospital Systems

6.2. Mobile In-Hospital Systems

6.3. Ambulance Deployable Systems

6.4. Field Deployable Systems

7. By Clinical Indication

7.1. Out-of-Hospital Cardiac Arrest (OHCA)

7.2. In-Hospital Cardiac Arrest (IHCA)

7.3. Acute Myocardial Infarction

7.4. Refractory Ventricular Fibrillation

7.5. Cardiogenic Shock

7.6. Pulmonary Embolism

7.7. Post-Cardiotomy Support

7.8. Bridge-to-Recovery

7.9. Bridge-to-Transplant

8. By Patient Population

8.1. Adult

8.2. Pediatric

8.3. Neonatal

9. By Care Setting

9.1. Academic Medical Centres

9.2. University Hospitals

9.3. Cardiac Specialty Centres

9.4. Trauma Centres

9.5. Emergency Departments

9.6. Intensive Care Units

9.7. Military Medical Facilities

10. By Deployment Model

10.1. Hospital-Owned Systems

10.2. Shared Regional ECPR Networks

10.3. Mobile Response Teams

10.4. Public-Private Emergency Response Programmes

11. By Procurement Model

11.1. Direct Capital Purchase

11.2. Leasing

11.3. Managed Equipment Service

11.4. Outcome-Based Procurement

11.5. Consortium Purchasing

12. By Regulatory Pathway

12.1. FDA Cleared Systems

12.2. CE Marked Systems

12.3. PMDA Approved Systems

12.4. NMPA Approved Systems

12.5. Country-Specific Approvals

13. By End User

13.1. Hospitals

13.2. Cardiac Centres

13.3. Emergency Care Networks

13.4. ECMO Centres of Excellence

13.5. Ambulance and EMS Providers

13.6. Military and Disaster Response Units

14. Buyer Intelligence and Demand Landscape

14.1. Buyer Segmentation

14.1.1. University Hospitals

14.1.2. Cardiac Excellence Centres

14.1.3. ECMO Reference Centres

14.1.4. Government Healthcare Systems

14.1.5. Private Hospital Groups

14.1.6. Emergency Medical Services

14.2. Buyer Company Types

14.2.1. Public Hospitals

14.2.2. Private Hospital Networks

14.2.3. Academic Institutions

14.2.4. Integrated Health Systems

14.2.5. Emergency Response Agencies

14.3. Country-Wise Buyer Mapping

14.3.1. Germany

14.3.2. France

14.3.3. United Kingdom

14.3.4. Italy

14.3.5. Spain

14.3.6. United States

14.3.7. Canada

14.3.8. Japan

14.3.9. South Korea

14.3.10. China

14.3.11. Australia

14.3.12. Saudi Arabia

14.3.13. United Arab Emirates (UAE)

14.4. Regional Demand Clusters

14.4.1. Western Europe

14.4.2. North America

14.4.3. East Asia

14.4.4. GCC Countries

14.5. Buyer Scale Classification

14.5.1. High-Volume ECMO Centres

14.5.2. Regional Referral Hospitals

14.5.3. Community Hospitals

14.5.4. Specialised Cardiac Institutes

14.6. Procurement Models

14.6.1. Direct Tender

14.6.2. GPO Procurement

14.6.3. Framework Agreements

14.6.4. Multi-Year Technology Contracts

14.6.5. Clinical Trial-Based Acquisition

14.7. Buying Triggers

14.7.1. Cardiac Arrest Programme Expansion

14.7.2. ECMO Capacity Expansion

14.7.3. Survival Outcome Improvement Initiatives

14.7.4. National Resuscitation Programmes

14.7.5. Emergency Medicine Modernisation

14.8. Decision-Maker Mapping

14.8.1. Chief Medical Officer

14.8.2. Chief of Cardiac Surgery

14.8.3. ECMO Programme Director

14.8.4. ICU Director

14.8.5. Emergency Department Director

14.8.6. Procurement Head

14.8.7. Biomedical Engineering Head

14.9. Budget Ownership

14.9.1. Cardiac Services

14.9.2. Critical Care Units

14.9.3. Capital Equipment Committees

14.9.4. Innovation Funds

14.9.5. Government Healthcare Programmes

14.10. Vendor Selection Criteria

14.10.1. Clinical Outcomes

14.10.2. Ease of Deployment

14.10.3. Portability

14.10.4. Total Cost of Ownership

14.10.5. Training Requirements

14.10.6. Regulatory Compliance

14.10.7. Service Infrastructure

14.11. Contract Value Bands

14.11.1. Below US$100K

14.11.2. US$100K-250K

14.11.3. US$250K-500K

14.11.4. Above US$500K

14.12. Sales Cycle Length

14.12.1. 3-6 Months

14.12.2. 6-12 Months

14.12.3. 12-24 Months

14.13. Strategic Relevance for Resuscitec

14.13.1. Portable ECPR Platform Adoption Expansion

14.13.2. ECMO Reference Centre Relationship Deepening

14.13.3. European Hospital Network Growth Opportunities

14.13.4. Emergency Response Programme Partnerships

15. By Region

15.1. Europe

15.2. North America

15.3. Asia-Pacific

15.4. Middle East and Africa

15.5. Latin America

16. Europe Extracorporeal Cardiopulmonary Resuscitation (ECPR) Devices Market - Global View with Spotlight on Product Types, Technology Architecture, Clinical Indications and Care Settings Market Analysis and Forecast (2026–2030)

16.1. Introduction

16.2. Market Share Analysis

16.3. Market Size and Forecast

16.4. Market Size and Forecast, By Geography

16.4.1. Germany

16.4.1.1. Market Share Analysis

16.4.1.2. Market Size and Forecast

16.4.1.3. By Product

16.4.1.4. By Technology

16.4.1.5. By Application

16.4.1.6. By Customer

16.4.1.7. Freiburg

16.4.1.7.1. Market Share Analysis

16.4.1.7.2. Market Size and Forecast

16.4.1.7.3. By Product

16.4.1.7.4. By Technology

16.4.1.7.5. By Application

16.4.1.7.6. By Customer

16.4.1.8. Berlin

16.4.1.8.1. Market Share Analysis

16.4.1.8.2. Market Size and Forecast

16.4.1.8.3. By Product

16.4.1.8.4. By Technology

16.4.1.8.5. By Application

16.4.1.8.6. By Customer

16.4.1.9. Munich

16.4.1.9.1. Market Share Analysis

16.4.1.9.2. Market Size and Forecast

16.4.1.9.3. By Product

16.4.1.9.4. By Technology

16.4.1.9.5. By Application

16.4.1.9.6. By Customer

16.4.1.10. Hamburg

16.4.1.10.1. Market Share Analysis

16.4.1.10.2. Market Size and Forecast

16.4.1.10.3. By Product

16.4.1.10.4. By Technology

16.4.1.10.5. By Application

16.4.1.10.6. By Customer

16.4.1.11. Cologne

16.4.1.11.1. Market Share Analysis

16.4.1.11.2. Market Size and Forecast

16.4.1.11.3. By Product

16.4.1.11.4. By Technology

16.4.1.11.5. By Application

16.4.1.11.6. By Customer

16.4.2. France

16.4.2.1. Market Share Analysis

16.4.2.2. Market Size and Forecast

16.4.2.3. By Product

16.4.2.4. By Technology

16.4.2.5. By Application

16.4.2.6. By Customer

16.4.2.7. Paris

16.4.2.7.1. Market Share Analysis

16.4.2.7.2. Market Size and Forecast

16.4.2.7.3. By Product

16.4.2.7.4. By Technology

16.4.2.7.5. By Application

16.4.2.7.6. By Customer

16.4.2.8. Lyon

16.4.2.8.1. Market Share Analysis

16.4.2.8.2. Market Size and Forecast

16.4.2.8.3. By Product

16.4.2.8.4. By Technology

16.4.2.8.5. By Application

16.4.2.8.6. By Customer

16.4.2.9. Marseille

16.4.2.9.1. Market Share Analysis

16.4.2.9.2. Market Size and Forecast

16.4.2.9.3. By Product

16.4.2.9.4. By Technology

16.4.2.9.5. By Application

16.4.2.9.6. By Customer

16.4.3. United Kingdom

16.4.3.1. Market Share Analysis

16.4.3.2. Market Size and Forecast

16.4.3.3. By Product

16.4.3.4. By Technology

16.4.3.5. By Application

16.4.3.6. By Customer

16.4.3.7. London

16.4.3.7.1. Market Share Analysis

16.4.3.7.2. Market Size and Forecast

16.4.3.7.3. By Product

16.4.3.7.4. By Technology

16.4.3.7.5. By Application

16.4.3.7.6. By Customer

16.4.3.8. Birmingham

16.4.3.8.1. Market Share Analysis

16.4.3.8.2. Market Size and Forecast

16.4.3.8.3. By Product

16.4.3.8.4. By Technology

16.4.3.8.5. By Application

16.4.3.8.6. By Customer

16.4.3.9. Manchester

16.4.3.9.1. Market Share Analysis

16.4.3.9.2. Market Size and Forecast

16.4.3.9.3. By Product

16.4.3.9.4. By Technology

16.4.3.9.5. By Application

16.4.3.9.6. By Customer

16.4.4. Italy

16.4.4.1. Market Share Analysis

16.4.4.2. Market Size and Forecast

16.4.4.3. By Product

16.4.4.4. By Technology

16.4.4.5. By Application

16.4.4.6. By Customer

16.4.4.7. Milan

16.4.4.7.1. Market Share Analysis

16.4.4.7.2. Market Size and Forecast

16.4.4.7.3. By Product

16.4.4.7.4. By Technology

16.4.4.7.5. By Application

16.4.4.7.6. By Customer

16.4.4.8. Rome

16.4.4.8.1. Market Share Analysis

16.4.4.8.2. Market Size and Forecast

16.4.4.8.3. By Product

16.4.4.8.4. By Technology

16.4.4.8.5. By Application

16.4.4.8.6. By Customer

16.4.5. Spain

16.4.5.1. Market Share Analysis

16.4.5.2. Market Size and Forecast

16.4.5.3. By Product

16.4.5.4. By Technology

16.4.5.5. By Application

16.4.5.6. By Customer

16.4.5.7. Madrid

16.4.5.7.1. Market Share Analysis

16.4.5.7.2. Market Size and Forecast

16.4.5.7.3. By Product

16.4.5.7.4. By Technology

16.4.5.7.5. By Application

16.4.5.7.6. By Customer

16.4.5.8. Barcelona

16.4.5.8.1. Market Share Analysis

16.4.5.8.2. Market Size and Forecast

16.4.5.8.3. By Product

16.4.5.8.4. By Technology

16.4.5.8.5. By Application

16.4.5.8.6. By Customer

16.4.6. Netherlands

16.4.6.1. Market Share Analysis

16.4.6.2. Market Size and Forecast

16.4.6.3. By Product

16.4.6.4. By Technology

16.4.6.5. By Application

16.4.6.6. By Customer

16.4.6.7. Amsterdam

16.4.6.7.1. Market Share Analysis

16.4.6.7.2. Market Size and Forecast

16.4.6.7.3. By Product

16.4.6.7.4. By Technology

16.4.6.7.5. By Application

16.4.6.7.6. By Customer

16.4.6.8. Rotterdam

16.4.6.8.1. Market Share Analysis

16.4.6.8.2. Market Size and Forecast

16.4.6.8.3. By Product

16.4.6.8.4. By Technology

16.4.6.8.5. By Application

16.4.6.8.6. By Customer

16.4.7. Switzerland

16.4.7.1. Market Share Analysis

16.4.7.2. Market Size and Forecast

16.4.7.3. By Product

16.4.7.4. By Technology

16.4.7.5. By Application

16.4.7.6. By Customer

16.4.7.7. Zurich

16.4.7.7.1. Market Share Analysis

16.4.7.7.2. Market Size and Forecast

16.4.7.7.3. By Product

16.4.7.7.4. By Technology

16.4.7.7.5. By Application

16.4.7.7.6. By Customer

16.4.7.8. Basel

16.4.7.8.1. Market Share Analysis

16.4.7.8.2. Market Size and Forecast

16.4.7.8.3. By Product

16.4.7.8.4. By Technology

16.4.7.8.5. By Application

16.4.7.8.6. By Customer

17. North America Extracorporeal Cardiopulmonary Resuscitation (ECPR) Devices Market - Global View with Spotlight on Product Types, Technology Architecture, Clinical Indications and Care Settings Market Analysis and Forecast (2026–2030)

17.1. Introduction

17.2. Market Share Analysis

17.3. Market Size and Forecast

17.4. Market Size and Forecast, By Geography

17.4.1. United States

17.4.1.1. Market Share Analysis

17.4.1.2. Market Size and Forecast

17.4.1.3. By Product

17.4.1.4. By Technology

17.4.1.5. By Application

17.4.1.6. By Customer

17.4.1.7. Boston

17.4.1.7.1. Market Share Analysis

17.4.1.7.2. Market Size and Forecast

17.4.1.7.3. By Product

17.4.1.7.4. By Technology

17.4.1.7.5. By Application

17.4.1.7.6. By Customer

17.4.1.8. Houston

17.4.1.8.1. Market Share Analysis

17.4.1.8.2. Market Size and Forecast

17.4.1.8.3. By Product

17.4.1.8.4. By Technology

17.4.1.8.5. By Application

17.4.1.8.6. By Customer

17.4.1.9. Cleveland

17.4.1.9.1. Market Share Analysis

17.4.1.9.2. Market Size and Forecast

17.4.1.9.3. By Product

17.4.1.9.4. By Technology

17.4.1.9.5. By Application

17.4.1.9.6. By Customer

17.4.1.10. Chicago

17.4.1.10.1. Market Share Analysis

17.4.1.10.2. Market Size and Forecast

17.4.1.10.3. By Product

17.4.1.10.4. By Technology

17.4.1.10.5. By Application

17.4.1.10.6. By Customer

17.4.1.11. New York

17.4.1.11.1. Market Share Analysis

17.4.1.11.2. Market Size and Forecast

17.4.1.11.3. By Product

17.4.1.11.4. By Technology

17.4.1.11.5. By Application

17.4.1.11.6. By Customer

17.4.1.12. Los Angeles

17.4.1.12.1. Market Share Analysis

17.4.1.12.2. Market Size and Forecast

17.4.1.12.3. By Product

17.4.1.12.4. By Technology

17.4.1.12.5. By Application

17.4.1.12.6. By Customer

17.4.2. Canada

17.4.2.1. Market Share Analysis

17.4.2.2. Market Size and Forecast

17.4.2.3. By Product

17.4.2.4. By Technology

17.4.2.5. By Application

17.4.2.6. By Customer

17.4.2.7. Toronto

17.4.2.7.1. Market Share Analysis

17.4.2.7.2. Market Size and Forecast

17.4.2.7.3. By Product

17.4.2.7.4. By Technology

17.4.2.7.5. By Application

17.4.2.7.6. By Customer

17.4.2.8. Montreal

17.4.2.8.1. Market Share Analysis

17.4.2.8.2. Market Size and Forecast

17.4.2.8.3. By Product

17.4.2.8.4. By Technology

17.4.2.8.5. By Application

17.4.2.8.6. By Customer

17.4.2.9. Vancouver

17.4.2.9.1. Market Share Analysis

17.4.2.9.2. Market Size and Forecast

17.4.2.9.3. By Product

17.4.2.9.4. By Technology

17.4.2.9.5. By Application

17.4.2.9.6. By Customer

18. Asia-Pacific Extracorporeal Cardiopulmonary Resuscitation (ECPR) Devices Market - Global View with Spotlight on Product Types, Technology Architecture, Clinical Indications and Care Settings Market Analysis and Forecast (2026–2030)

18.1. Introduction

18.2. Market Share Analysis

18.3. Market Size and Forecast

18.4. Market Size and Forecast, By Geography

18.4.1. Japan

18.4.1.1. Market Share Analysis

18.4.1.2. Market Size and Forecast

18.4.1.3. By Product

18.4.1.4. By Technology

18.4.1.5. By Application

18.4.1.6. By Customer

18.4.1.7. Tokyo

18.4.1.7.1. Market Share Analysis

18.4.1.7.2. Market Size and Forecast

18.4.1.7.3. By Product

18.4.1.7.4. By Technology

18.4.1.7.5. By Application

18.4.1.7.6. By Customer

18.4.1.8. Osaka

18.4.1.8.1. Market Share Analysis

18.4.1.8.2. Market Size and Forecast

18.4.1.8.3. By Product

18.4.1.8.4. By Technology

18.4.1.8.5. By Application

18.4.1.8.6. By Customer

18.4.2. South Korea

18.4.2.1. Market Share Analysis

18.4.2.2. Market Size and Forecast

18.4.2.3. By Product

18.4.2.4. By Technology

18.4.2.5. By Application

18.4.2.6. By Customer

18.4.2.7. Seoul

18.4.2.7.1. Market Share Analysis

18.4.2.7.2. Market Size and Forecast

18.4.2.7.3. By Product

18.4.2.7.4. By Technology

18.4.2.7.5. By Application

18.4.2.7.6. By Customer

18.4.2.8. Busan

18.4.2.8.1. Market Share Analysis

18.4.2.8.2. Market Size and Forecast

18.4.2.8.3. By Product

18.4.2.8.4. By Technology

18.4.2.8.5. By Application

18.4.2.8.6. By Customer

18.4.3. China

18.4.3.1. Market Share Analysis

18.4.3.2. Market Size and Forecast

18.4.3.3. By Product

18.4.3.4. By Technology

18.4.3.5. By Application

18.4.3.6. By Customer

18.4.3.7. Beijing

18.4.3.7.1. Market Share Analysis

18.4.3.7.2. Market Size and Forecast

18.4.3.7.3. By Product

18.4.3.7.4. By Technology

18.4.3.7.5. By Application

18.4.3.7.6. By Customer

18.4.3.8. Shanghai

18.4.3.8.1. Market Share Analysis

18.4.3.8.2. Market Size and Forecast

18.4.3.8.3. By Product

18.4.3.8.4. By Technology

18.4.3.8.5. By Application

18.4.3.8.6. By Customer

18.4.3.9. Shenzhen

18.4.3.9.1. Market Share Analysis

18.4.3.9.2. Market Size and Forecast

18.4.3.9.3. By Product

18.4.3.9.4. By Technology

18.4.3.9.5. By Application

18.4.3.9.6. By Customer

18.4.4. Australia

18.4.4.1. Market Share Analysis

18.4.4.2. Market Size and Forecast

18.4.4.3. By Product

18.4.4.4. By Technology

18.4.4.5. By Application

18.4.4.6. By Customer

18.4.4.7. Sydney

18.4.4.7.1. Market Share Analysis

18.4.4.7.2. Market Size and Forecast

18.4.4.7.3. By Product

18.4.4.7.4. By Technology

18.4.4.7.5. By Application

18.4.4.7.6. By Customer

18.4.4.8. Melbourne

18.4.4.8.1. Market Share Analysis

18.4.4.8.2. Market Size and Forecast

18.4.4.8.3. By Product

18.4.4.8.4. By Technology

18.4.4.8.5. By Application

18.4.4.8.6. By Customer

18.4.5. Singapore

18.4.5.1. Market Share Analysis

18.4.5.2. Market Size and Forecast

18.4.5.3. By Product

18.4.5.4. By Technology

18.4.5.5. By Application

18.4.5.6. By Customer

19. Middle East and Africa Extracorporeal Cardiopulmonary Resuscitation (ECPR) Devices Market - Global View with Spotlight on Product Types, Technology Architecture, Clinical Indications and Care Settings Market Analysis and Forecast (2026–2030)

19.1. Introduction

19.2. Market Share Analysis

19.3. Market Size and Forecast

19.4. Market Size and Forecast, By Geography

19.4.1. Saudi Arabia

19.4.1.1. Market Share Analysis

19.4.1.2. Market Size and Forecast

19.4.1.3. By Product

19.4.1.4. By Technology

19.4.1.5. By Application

19.4.1.6. By Customer

19.4.1.7. Riyadh

19.4.1.7.1. Market Share Analysis

19.4.1.7.2. Market Size and Forecast

19.4.1.7.3. By Product

19.4.1.7.4. By Technology

19.4.1.7.5. By Application

19.4.1.7.6. By Customer

19.4.1.8. Jeddah

19.4.1.8.1. Market Share Analysis

19.4.1.8.2. Market Size and Forecast

19.4.1.8.3. By Product

19.4.1.8.4. By Technology

19.4.1.8.5. By Application

19.4.1.8.6. By Customer

19.4.2. United Arab Emirates (UAE)

19.4.2.1. Market Share Analysis

19.4.2.2. Market Size and Forecast

19.4.2.3. By Product

19.4.2.4. By Technology

19.4.2.5. By Application

19.4.2.6. By Customer

19.4.2.7. Dubai

19.4.2.7.1. Market Share Analysis

19.4.2.7.2. Market Size and Forecast

19.4.2.7.3. By Product

19.4.2.7.4. By Technology

19.4.2.7.5. By Application

19.4.2.7.6. By Customer

19.4.2.8. Abu Dhabi

19.4.2.8.1. Market Share Analysis

19.4.2.8.2. Market Size and Forecast

19.4.2.8.3. By Product

19.4.2.8.4. By Technology

19.4.2.8.5. By Application

19.4.2.8.6. By Customer

19.4.3. South Africa

19.4.3.1. Market Share Analysis

19.4.3.2. Market Size and Forecast

19.4.3.3. By Product

19.4.3.4. By Technology

19.4.3.5. By Application

19.4.3.6. By Customer

19.4.3.7. Johannesburg

19.4.3.7.1. Market Share Analysis

19.4.3.7.2. Market Size and Forecast

19.4.3.7.3. By Product

19.4.3.7.4. By Technology

19.4.3.7.5. By Application

19.4.3.7.6. By Customer

19.4.3.8. Cape Town

19.4.3.8.1. Market Share Analysis

19.4.3.8.2. Market Size and Forecast

19.4.3.8.3. By Product

19.4.3.8.4. By Technology

19.4.3.8.5. By Application

19.4.3.8.6. By Customer

20. Latin America Extracorporeal Cardiopulmonary Resuscitation (ECPR) Devices Market - Global View with Spotlight on Product Types, Technology Architecture, Clinical Indications and Care Settings Market Analysis and Forecast (2026–2030)

20.1. Introduction

20.2. Market Share Analysis

20.3. Market Size and Forecast

20.4. Market Size and Forecast, By Geography

20.4.1. Brazil

20.4.1.1. Market Share Analysis

20.4.1.2. Market Size and Forecast

20.4.1.3. By Product

20.4.1.4. By Technology

20.4.1.5. By Application

20.4.1.6. By Customer

20.4.1.7. Sao Paulo

20.4.1.7.1. Market Share Analysis

20.4.1.7.2. Market Size and Forecast

20.4.1.7.3. By Product

20.4.1.7.4. By Technology

20.4.1.7.5. By Application

20.4.1.7.6. By Customer

20.4.1.8. Rio De Janeiro

20.4.1.8.1. Market Share Analysis

20.4.1.8.2. Market Size and Forecast

20.4.1.8.3. By Product

20.4.1.8.4. By Technology

20.4.1.8.5. By Application

20.4.1.8.6. By Customer

20.4.2. Mexico

20.4.2.1. Market Share Analysis

20.4.2.2. Market Size and Forecast

20.4.2.3. By Product

20.4.2.4. By Technology

20.4.2.5. By Application

20.4.2.6. By Customer

20.4.2.7. Mexico City

20.4.2.7.1. Market Share Analysis

20.4.2.7.2. Market Size and Forecast

20.4.2.7.3. By Product

20.4.2.7.4. By Technology

20.4.2.7.5. By Application

20.4.2.7.6. By Customer

20.4.2.8. Monterrey

20.4.2.8.1. Market Share Analysis

20.4.2.8.2. Market Size and Forecast

20.4.2.8.3. By Product

20.4.2.8.4. By Technology

20.4.2.8.5. By Application

20.4.2.8.6. By Customer

21. Competition Analysis

21.1. Market Positioning Overview

21.1.1. Global Leaders

21.1.2. Regional Specialists

21.1.3. Emerging Innovators

21.1.4. Academic Spin-Off Companies

21.2. Competitive Benchmarking Metrics

21.2.1. Estimated Market Position

21.2.2. Product Portfolio Depth

21.2.3. Portability

21.2.4. Clinical Evidence

21.2.5. Installed Base

21.2.6. Distribution Reach

21.2.7. Service Network

21.2.8. Regulatory Coverage

21.2.9. Innovation Pipeline

21.3. Strategic Moves

21.3.1. Product Launches

21.3.2. Clinical Collaborations

21.3.3. Hospital Partnerships

21.3.4. ECMO Programme Alliances

21.3.5. Research Investments

21.3.6. Geographic Expansion

21.4. Competitive Mapping & Gaps

21.4.1. Technology Opportunity Areas

21.4.2. Clinical Workflow Gaps

21.4.3. Portability Gaps

21.4.4. Cost Optimisation Opportunities

21.4.5. Emerging Market Opportunities

22. Company Profiles

22.1. Resuscitec GmbH

22.1.1. Company Overview

22.1.2. Headquarters, Ownership and Workforce

22.1.3. Geographic Footprint

22.1.4. Product Portfolio

22.1.5. ECPR and ECMO Capabilities

22.1.6. Target Customers

22.1.7. Distribution Strategy

22.1.8. Revenue Indicators

22.1.9. Certifications and Regulatory Status

22.1.10. Partnerships and Alliances

22.1.11. R&D Activities

22.1.12. Innovation Pipeline

22.1.13. Recent Developments

22.1.14. SWOT Analysis

22.2. Getinge

22.2.1. Company Overview

22.2.2. Headquarters, Ownership and Workforce

22.2.3. Geographic Footprint

22.2.4. Product Portfolio

22.2.5. ECPR and ECMO Capabilities

22.2.6. Target Customers

22.2.7. Distribution Strategy

22.2.8. Revenue Indicators

22.2.9. Certifications and Regulatory Status

22.2.10. Partnerships and Alliances

22.2.11. R&D Activities

22.2.12. Innovation Pipeline

22.2.13. Recent Developments

22.2.14. SWOT Analysis

22.3. LivaNova

22.3.1. Company Overview

22.3.2. Headquarters, Ownership and Workforce

22.3.3. Geographic Footprint

22.3.4. Product Portfolio

22.3.5. ECPR and ECMO Capabilities

22.3.6. Target Customers

22.3.7. Distribution Strategy

22.3.8. Revenue Indicators

22.3.9. Certifications and Regulatory Status

22.3.10. Partnerships and Alliances

22.3.11. R&D Activities

22.3.12. Innovation Pipeline

22.3.13. Recent Developments

22.3.14. SWOT Analysis

22.4. Medtronic

22.4.1. Company Overview

22.4.2. Headquarters, Ownership and Workforce

22.4.3. Geographic Footprint

22.4.4. Product Portfolio

22.4.5. ECPR and ECMO Capabilities

22.4.6. Target Customers

22.4.7. Distribution Strategy

22.4.8. Revenue Indicators

22.4.9. Certifications and Regulatory Status

22.4.10. Partnerships and Alliances

22.4.11. R&D Activities

22.4.12. Innovation Pipeline

22.4.13. Recent Developments

22.4.14. SWOT Analysis

22.5. Abbott

22.5.1. Company Overview

22.5.2. Headquarters, Ownership and Workforce

22.5.3. Geographic Footprint

22.5.4. Product Portfolio

22.5.5. ECPR and ECMO Capabilities

22.5.6. Target Customers

22.5.7. Distribution Strategy

22.5.8. Revenue Indicators

22.5.9. Certifications and Regulatory Status

22.5.10. Partnerships and Alliances

22.5.11. R&D Activities

22.5.12. Innovation Pipeline

22.5.13. Recent Developments

22.5.14. SWOT Analysis

22.6. Terumo Corporation

22.6.1. Company Overview

22.6.2. Headquarters, Ownership and Workforce

22.6.3. Geographic Footprint

22.6.4. Product Portfolio

22.6.5. ECPR and ECMO Capabilities

22.6.6. Target Customers

22.6.7. Distribution Strategy

22.6.8. Revenue Indicators

22.6.9. Certifications and Regulatory Status

22.6.10. Partnerships and Alliances

22.6.11. R&D Activities

22.6.12. Innovation Pipeline

22.6.13. Recent Developments

22.6.14. SWOT Analysis

22.7. Fresenius Medical Care

22.7.1. Company Overview

22.7.2. Headquarters, Ownership and Workforce

22.7.3. Geographic Footprint

22.7.4. Product Portfolio

22.7.5. ECPR and ECMO Capabilities

22.7.6. Target Customers

22.7.7. Distribution Strategy

22.7.8. Revenue Indicators

22.7.9. Certifications and Regulatory Status

22.7.10. Partnerships and Alliances

22.7.11. R&D Activities

22.7.12. Innovation Pipeline

22.7.13. Recent Developments

22.7.14. SWOT Analysis

22.8. Eurosets

22.8.1. Company Overview

22.8.2. Headquarters, Ownership and Workforce

22.8.3. Geographic Footprint

22.8.4. Product Portfolio

22.8.5. ECPR and ECMO Capabilities

22.8.6. Target Customers

22.8.7. Distribution Strategy

22.8.8. Revenue Indicators

22.8.9. Certifications and Regulatory Status

22.8.10. Partnerships and Alliances

22.8.11. R&D Activities

22.8.12. Innovation Pipeline

22.8.13. Recent Developments

22.8.14. SWOT Analysis

22.9. Xenios AG

22.9.1. Company Overview

22.9.2. Headquarters, Ownership and Workforce

22.9.3. Geographic Footprint

22.9.4. Product Portfolio

22.9.5. ECPR and ECMO Capabilities

22.9.6. Target Customers

22.9.7. Distribution Strategy

22.9.8. Revenue Indicators

22.9.9. Certifications and Regulatory Status

22.9.10. Partnerships and Alliances

22.9.11. R&D Activities

22.9.12. Innovation Pipeline

22.9.13. Recent Developments

22.9.14. SWOT Analysis

22.10. Inspira Technologies

22.10.1. Company Overview

22.10.2. Headquarters, Ownership and Workforce

22.10.3. Geographic Footprint

22.10.4. Product Portfolio

22.10.5. ECPR and ECMO Capabilities

22.10.6. Target Customers

22.10.7. Distribution Strategy

22.10.8. Revenue Indicators

22.10.9. Certifications and Regulatory Status

22.10.10. Partnerships and Alliances

22.10.11. R&D Activities

22.10.12. Innovation Pipeline

22.10.13. Recent Developments

22.10.14. SWOT Analysis

22.11. Spectrum Medical

22.11.1. Company Overview

22.11.2. Headquarters, Ownership and Workforce

22.11.3. Geographic Footprint

22.11.4. Product Portfolio

22.11.5. ECPR and ECMO Capabilities

22.11.6. Target Customers

22.11.7. Distribution Strategy

22.11.8. Revenue Indicators

22.11.9. Certifications and Regulatory Status

22.11.10. Partnerships and Alliances

22.11.11. R&D Activities

22.11.12. Innovation Pipeline

22.11.13. Recent Developments

22.11.14. SWOT Analysis

22.12. Breethe Inc.

22.12.1. Company Overview

22.12.2. Headquarters, Ownership and Workforce

22.12.3. Geographic Footprint

22.12.4. Product Portfolio

22.12.5. ECPR and ECMO Capabilities

22.12.6. Target Customers

22.12.7. Distribution Strategy

22.12.8. Revenue Indicators

22.12.9. Certifications and Regulatory Status

22.12.10. Partnerships and Alliances

22.12.11. R&D Activities

22.12.12. Innovation Pipeline

22.12.13. Recent Developments

22.12.14. SWOT Analysis

22.13. ECLS Systems

22.13.1. Company Overview

22.13.2. Headquarters, Ownership and Workforce

22.13.3. Geographic Footprint

22.13.4. Product Portfolio

22.13.5. ECPR and ECMO Capabilities

22.13.6. Target Customers

22.13.7. Distribution Strategy

22.13.8. Revenue Indicators

22.13.9. Certifications and Regulatory Status

22.13.10. Partnerships and Alliances

22.13.11. R&D Activities

22.13.12. Innovation Pipeline

22.13.13. Recent Developments

22.13.14. SWOT Analysis

22.14. Senko Medical

22.14.1. Company Overview

22.14.2. Headquarters, Ownership and Workforce

22.14.3. Geographic Footprint

22.14.4. Product Portfolio

22.14.5. ECPR and ECMO Capabilities

22.14.6. Target Customers

22.14.7. Distribution Strategy

22.14.8. Revenue Indicators

22.14.9. Certifications and Regulatory Status

22.14.10. Partnerships and Alliances

22.14.11. R&D Activities

22.14.12. Innovation Pipeline

22.14.13. Recent Developments

22.14.14. SWOT Analysis

22.15. Nipro Corporation

22.15.1. Company Overview

22.15.2. Headquarters, Ownership and Workforce

22.15.3. Geographic Footprint

22.15.4. Product Portfolio

22.15.5. ECPR and ECMO Capabilities

22.15.6. Target Customers

22.15.7. Distribution Strategy

22.15.8. Revenue Indicators

22.15.9. Certifications and Regulatory Status

22.15.10. Partnerships and Alliances

22.15.11. R&D Activities

22.15.12. Innovation Pipeline

22.15.13. Recent Developments

22.15.14. SWOT Analysis

22.16. MicroPort Scientific

22.16.1. Company Overview

22.16.2. Headquarters, Ownership and Workforce

22.16.3. Geographic Footprint

22.16.4. Product Portfolio

22.16.5. ECPR and ECMO Capabilities

22.16.6. Target Customers

22.16.7. Distribution Strategy

22.16.8. Revenue Indicators

22.16.9. Certifications and Regulatory Status

22.16.10. Partnerships and Alliances

22.16.11. R&D Activities

22.16.12. Innovation Pipeline

22.16.13. Recent Developments

22.16.14. SWOT Analysis

22.17. OriGen Biomedical

22.17.1. Company Overview

22.17.2. Headquarters, Ownership and Workforce

22.17.3. Geographic Footprint

22.17.4. Product Portfolio

22.17.5. ECPR and ECMO Capabilities

22.17.6. Target Customers

22.17.7. Distribution Strategy

22.17.8. Revenue Indicators

22.17.9. Certifications and Regulatory Status

22.17.10. Partnerships and Alliances

22.17.11. R&D Activities

22.17.12. Innovation Pipeline

22.17.13. Recent Developments

22.17.14. SWOT Analysis

22.18. MC3 Cardiopulmonary

22.18.1. Company Overview

22.18.2. Headquarters, Ownership and Workforce

22.18.3. Geographic Footprint

22.18.4. Product Portfolio

22.18.5. ECPR and ECMO Capabilities

22.18.6. Target Customers

22.18.7. Distribution Strategy

22.18.8. Revenue Indicators

22.18.9. Certifications and Regulatory Status

22.18.10. Partnerships and Alliances

22.18.11. R&D Activities

22.18.12. Innovation Pipeline

22.18.13. Recent Developments

22.18.14. SWOT Analysis

22.19. ALung Technologies

22.19.1. Company Overview

22.19.2. Headquarters, Ownership and Workforce

22.19.3. Geographic Footprint

22.19.4. Product Portfolio

22.19.5. ECPR and ECMO Capabilities

22.19.6. Target Customers

22.19.7. Distribution Strategy

22.19.8. Revenue Indicators

22.19.9. Certifications and Regulatory Status

22.19.10. Partnerships and Alliances

22.19.11. R&D Activities

22.19.12. Innovation Pipeline

22.19.13. Recent Developments

22.19.14. SWOT Analysis

22.20. Medos

22.20.1. Company Overview

22.20.2. Headquarters, Ownership and Workforce

22.20.3. Geographic Footprint

22.20.4. Product Portfolio

22.20.5. ECPR and ECMO Capabilities

22.20.6. Target Customers

22.20.7. Distribution Strategy

22.20.8. Revenue Indicators

22.20.9. Certifications and Regulatory Status

22.20.10. Partnerships and Alliances

22.20.11. R&D Activities

22.20.12. Innovation Pipeline

22.20.13. Recent Developments

22.20.14. SWOT Analysis

Frequently Asked Questions

The market is estimated at approximately USD 420 Million in 2025 and is projected to reach approximately USD 680 Million by 2030, expanding at a compound annual growth rate of roughly 10.1 percent.

A category of systems and components, including complete ECPR systems, cannulation kits, perfusion pumps, oxygenators and monitoring equipment, used to establish emergency extracorporeal blood flow during cardiac arrest resuscitation efforts. This report describes the category strictly as a market segment, not as a statement of clinical effectiveness.

ECPR systems and ECMO-based ECPR platforms represent the largest product category by installed base, reflecting concentration within established, fixed hospital ECMO programmes.

Europe leads current demand, anchored by established ECMO reference centre networks across Germany, France, the United Kingdom, Italy, Spain, the Netherlands and Switzerland.

Middle East and Africa is the fastest-growing region tracked in this report, reflecting expanding national resuscitation programme investment in GCC countries.

Four architectures: conventional ECMO-based ECPR, compact mobile ECPR systems, integrated automated ECPR platforms and hybrid ECPR solutions, each shaping which portability tier a system belongs to.

Nine indications tracked in this report, including out-of-hospital and in-hospital cardiac arrest, cardiogenic shock, pulmonary embolism, post-cardiotomy support, and bridge-to-recovery and bridge-to-transplant scenarios.

FDA clearance, CE marking, PMDA and NMPA approval, and country-specific approval pathways, each shaping which markets a given ECPR system can access.

Twenty companies are profiled in this report, spanning global life-support manufacturers, specialist ECPR and ECMO platform companies, and emerging innovators and academic spin-off companies.

Inquire Before Buying Request Free Sample Ask For Discount

Sized as a distinct segment within the broader ECMO device market

No independent research firm publishes a market size figure specific to ECPR devices alone. This estimate starts from the broader global ECMO (extracorporeal membrane oxygenation) device market, which covers all ECMO applications including respiratory support, cardiac support and cardiopulmonary resuscitation, then narrows to the ECPR-specific share of that category.

Derivation from independently published ECMO device market estimates

Published estimates for the global ECMO device market vary by scope and methodology, ranging from approximately USD 0.65 Billion to USD 1.69 Billion for 2025 across several research providers. This report adopts a mid-range base of approximately USD 1.15 Billion in 2025, growing to approximately USD 1.69 Billion by 2030 at a CAGR of approximately 7.9 percent, reflecting a broad definition of the category that includes complete systems, cannulation, perfusion and oxygenation components.

ECPR-specific narrowing

ECPR-specific systems and disposables, complete ECPR systems, cannulation kits, perfusion pumps, oxygenators and monitoring systems procured specifically for resuscitation programmes, are estimated to represent approximately 36 percent of the broader ECMO device base, which also serves non-resuscitation respiratory and cardiac support applications. Applying this share to the 2025 base produces the adopted starting figure of approximately USD 420 Million.

Forecast CAGR reflecting the segment's documented faster growth

Independent industry commentary identifies ECPR as the fastest-growing application within the broader ECMO device market, with cited compound annual growth rates ranging from approximately 9.5 percent to 13.4 percent across different sources and regional scopes. This report adopts approximately 10.1 percent, toward the conservative middle of that published range, producing the forecast of approximately USD 680 Million by 2030.

Frequently Asked Questions

The market is estimated at approximately USD 420 Million in 2025 and is projected to reach approximately USD 680 Million by 2030, expanding at a compound annual growth rate of roughly 10.1 percent.

A category of systems and components, including complete ECPR systems, cannulation kits, perfusion pumps, oxygenators and monitoring equipment, used to establish emergency extracorporeal blood flow during cardiac arrest resuscitation efforts. This report describes the category strictly as a market segment, not as a statement of clinical effectiveness.

ECPR systems and ECMO-based ECPR platforms represent the largest product category by installed base, reflecting concentration within established, fixed hospital ECMO programmes.

Europe leads current demand, anchored by established ECMO reference centre networks across Germany, France, the United Kingdom, Italy, Spain, the Netherlands and Switzerland.

Middle East and Africa is the fastest-growing region tracked in this report, reflecting expanding national resuscitation programme investment in GCC countries.

Four architectures: conventional ECMO-based ECPR, compact mobile ECPR systems, integrated automated ECPR platforms and hybrid ECPR solutions, each shaping which portability tier a system belongs to.

Nine indications tracked in this report, including out-of-hospital and in-hospital cardiac arrest, cardiogenic shock, pulmonary embolism, post-cardiotomy support, and bridge-to-recovery and bridge-to-transplant scenarios.

FDA clearance, CE marking, PMDA and NMPA approval, and country-specific approval pathways, each shaping which markets a given ECPR system can access.

Twenty companies are profiled in this report, spanning global life-support manufacturers, specialist ECPR and ECMO platform companies, and emerging innovators and academic spin-off companies.

Inquire Before Buying Request Free Sample Ask For Discount